Chat with an Expert

StemSpan™ Erythroid Expansion Supplement (100X)

Serum-free culture supplement for expansion of human erythroid cells

More Views

StemSpan™ Erythroid Expansion Supplement (100X)

Serum-free culture supplement for expansion of human erythroid cells

1 mL
Catalog #02692
604 USD

Overview

StemSpan™ Erythroid Expansion Supplement (100X) contains a combination of recombinant human cytokines (SCF, IL-3, and EPO) formulated to selectively promote the expansion and differentiation of erythroid progenitor cells from CD34+ cells isolated from human cord blood (CB) or bone marrow (BM) samples. StemSpan™ Erythroid Expansion Supplement is intended for use in combination with StemSpan™ SFEM, SFEM II, and StemSpan™ Erythroid Expansion Medium (ACF-E), or any other media for culturing human hematopoietic cells. When added to serum-free medium, StemSpan™ Erythroid Expansion Supplement typically promotes the production of thousands of erythroid cells per input CD34+ cell in 14-day liquid cultures initiated with CD34+ human CB cells. See data section for more details.
Advantages:
• Formulated to produce large numbers of human erythroid cells in liquid cultures initiated with CD34+ CB or BM cells.


• Optimized for use with StemSpan™ media. When combined with StemSpan™ SFEM II in particular, supports up to 4-fold higher expansion of erythroid cells from human CD34+ CB cells than other serum-free media on the market.
• Supplied as a 100X concentrate. After thawing and mixing, the tube contents can be added directly to any hematopoietic cell expansion medium of choice.
Contains:
• Recombinant human stem cell factor (SCF)
• Recombinant human interleukin 3 (IL-3)
• Recombinant human erythropoietin (EPO)
Subtype:
Supplements
Cell Type:
Erythroid Cells; Hematopoietic Stem and Progenitor Cells
Species:
Human
Application:
Cell Culture; Differentiation; Expansion
Brand:
StemSpan
Area of Interest:
Stem Cell Biology; Transplantation Research
Formulation:
Serum-Free; Defined

Scientific Resources

Product Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Data and Publications

Data

CD71+GlyA+ Cells Produced from Cord Blood-Derived CD34+ Cells During 7 - 14 Days of Culture in StemSpan™ SFEM II Medium with Erythroid Expansion Supplement

Figure 1. CD71+GlyA+ Cells Produced from Cord Blood-Derived CD34+ Cells During 7 - 14 Days of Culture in StemSpan™ SFEM II Medium with Erythroid Expansion Supplement

Cord blood (CB)-derived CD34+ cells were cultured in StemSpan™ SFEM II containing Erythroid Expansion Supplement. After (A) 7 days and (B) 14 days, the cultured cells were stained with CD71 (Catalog #60106) and GlyA (Catalog #10423) antibodies and analyzed by flow cytometry. (A) During differentiation, the CD34+ cells progress to the CD71+GlyA+ erythroblast stage via CD71+GlyA- progenitors and pro-erythroblasts, which are still abundant on day 7. (B) With further culture these cells differentiate into erythroblasts and by day 14 most cells have become CD71+GlyA+. A small population of cells may mature further in these cultures into CD71-/loGlyA+ normoblasts and reticulocytes.

Production of Erythroid Cells from Human Cord Blood-Derived CD34+ Cells Cultured in StemSpan™ Media Containing StemSpan™ Erythroid Expansion Supplement

Figure 2. Production of Erythroid Cells from Human Cord Blood-Derived CD34+ Cells Cultured in StemSpan™ Media Containing StemSpan™ Erythroid Expansion Supplement

A) Average numbers of erythroid cells generated after culturing purified CD34+ cord blood (CB) cells (n=15) for 14 days in StemSpan™ SFEM (gray bars), SFEM II (gold bars) or ACF-E (brown bars) media containing Erythroid Expansion Supplement. Shown are the number of erythroid cells that express CD71 and/or GlyA per input CD34+ cell.
B) The percentages of the different erythroid cell subsets generated in these cultures are shown, including CD71-/loGlyA+ normoblasts, CD71+GlyA+ erythroblasts, and immature CD71+GlyA- erythroid progenitors and pro-erythroblasts. Vertical lines indicate 95% confidence limits (CL). Erythroid cell yields were significantly higher in SFEM II and ACF-E than in SFEM (p < 0.05;paired t-test, n=15). See table 1 for values and 95% confidence limits.

Table 1. Production of Erythroid Cells from Human Cord Blood-Derived CD34+ Cells Cultured in StemSpan™ Media Containing StemSpan™ Erythroid Expansion Supplement

Production of Erythroid Cells from Human Cord Blood-Derived CD34+ Cells Cultured in StemSpan™ Media Containing StemSpan™ Erythroid Expansion Supplement

Yields and percentages of erythroid cells produced after culturing purified CD34+ cord blood (CB) cells (n=15) for 14 days in StemSpan™ SFEM, SFEM II or ACF-E media containing Erythroid Expansion Supplement. Erythroid cells were identified by flow cytometry after staining with antibodies against CD71 and GlyA. The % erythroid cells represent the percentage of cells that express CD71 and/or GlyA. *CL: confidence limits.

Publications

(3)
Stem cell research 2017

Peripheral blood derived induced pluripotent stem cells (iPSCs) from a female with familial hypertrophic cardiomyopathy.

S. B. Ross et al.

Abstract

Induced pluripotent stem cells (iPSCs) were generated from peripheral blood mononuclear cells (PBMCs) obtained from a 62-year-old female with familial hypertrophic cardiomyopathy (HCM). PBMCs were reprogrammed to a pluripotent state following transfection with non-integrative episomal vectors carrying reprogramming factors OCT4, SOX2, LIN28, KLF4 and L-MYC. iPSCs were shown to express pluripotency markers, possess trilineage differentiation potential, carry rare variants identified in DNA isolated directly from the patient's whole blood, have a normal karyotype and no longer carry episomal vectors for reprogramming. This line is a useful resource for identifying unknown genetic causes of HCM.
Stem cell research 2017

Generation of induced pluripotent stem cells (iPSCs) from a hypertrophic cardiomyopathy patient with the pathogenic variant p.Val698Ala in beta-myosin heavy chain (MYH7) gene.

S. B. Ross et al.

Abstract

Induced pluripotent stem cells (iPSCs) were generated from peripheral blood mononuclear cells (PBMCs) isolated from the whole blood of a 43-year-old male with hypertrophic cardiomyopathy (HCM) who carries the pathogenic variant p.Val698Ala in beta-myosin heavy chain (MYH7). Patient-derived PBMCs were reprogrammed using non-integrative episomal vectors containing reprogramming factors OCT4, SOX2, LIN28, KLF4 and L-MYC. iPSCs were shown to express pluripotent markers, have trilineage differentiation potential, carry the pathogenic MYH7 variant p.Val698Ala, have a normal karyotype and no longer carry the episomal reprogramming vector. This line is useful for studying the link between variants in MYH7 and the pathogenesis of HCM.
Science translational medicine 2016 OCT

Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells.

DeWitt MA et al.

Abstract

Genetic diseases of blood cells are prime candidates for treatment through ex vivo gene editing of CD34(+) hematopoietic stem/progenitor cells (HSPCs), and a variety of technologies have been proposed to treat these disorders. Sickle cell disease (SCD) is a recessive genetic disorder caused by a single-nucleotide polymorphism in the β-globin gene (HBB). Sickle hemoglobin damages erythrocytes, causing vasoocclusion, severe pain, progressive organ damage, and premature death. We optimize design and delivery parameters of a ribonucleoprotein (RNP) complex comprising Cas9 protein and unmodified single guide RNA, together with a single-stranded DNA oligonucleotide donor (ssODN), to enable efficient replacement of the SCD mutation in human HSPCs. Corrected HSPCs from SCD patients produced less sickle hemoglobin RNA and protein and correspondingly increased wild-type hemoglobin when differentiated into erythroblasts. When engrafted into immunocompromised mice, ex vivo treated human HSPCs maintain SCD gene edits throughout 16 weeks at a level likely to have clinical benefit. These results demonstrate that an accessible approach combining Cas9 RNP with an ssODN can mediate efficient HSPC genome editing, enables investigator-led exploration of gene editing reagents in primary hematopoietic stem cells, and suggests a path toward the development of new gene editing treatments for SCD and other hematopoietic diseases.
STEMCELL TECHNOLOGIES INC.’S QUALITY MANAGEMENT SYSTEM IS CERTIFIED TO ISO 13485. PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED.